Why CorVel’s Latest Earnings Matter For Investors

CorVel (CRVL) reported first quarter 2026 results on 5 August, with higher sales, net income, and earnings per share compared with the same period a year earlier, drawing fresh attention to the stock.

The company also updated investors on recent share repurchases alongside the earnings release. This adds another factor for you to weigh when assessing CorVel’s valuation and longer term return potential.

CorVel’s recent earnings and ongoing buybacks have come alongside mixed share price performance, with a 90 day share price return of 9.77% but a 1 year total shareholder return that declined 27.42%. This suggests that long term momentum has faded despite a shorter term lift.

If CorVel’s results have you rethinking where growth could come from next, it may be worth scanning for other healthcare companies using artificial intelligence through the 43 healthcare AI stocks

CorVel’s business has delivered higher quarterly sales and earnings alongside ongoing buybacks, yet the stock is still down over the past year. Do those fundamentals now line up with a fair price, or do they suggest a potential mismatch?

Price-to-Earnings of 27.7x: Is It Justified For CorVel?

On a simple P/E comparison, CorVel trades on 27.7x earnings, which screens as more expensive than much of the US Healthcare sector despite the recent share price pullback.

The P/E ratio compares the current share price with earnings per share, so it reflects what investors are currently willing to pay for each dollar of profit. For a business like CorVel, which already reports high quality earnings and an 11.7% net profit margin, a higher P/E can indicate the market is building in expectations that these earnings will at least hold up.

CorVel’s recent 14.4% earnings growth over the past year, roughly in line with its 5 year earnings growth of 14.2% per year, helps explain why investors may accept a P/E above some healthcare peers. However, there is no clear analyst forecast in the data, so it is not possible to say whether this multiple reflects optimistic, cautious, or neutral profit expectations over the next few years.

Compared with the broader US Healthcare industry P/E of 25.3x, CorVel’s 27.7x multiple stands out as higher, while still screening as good value against a peer average of 60.7x in its closer comparison set. That mix of a premium to the industry and a discount to peers suggests investors are pricing CorVel above the sector average but not at the top end of its narrower peer group.

Result: Price-to-Earnings of 27.7x (ABOUT RIGHT)

However, CorVel’s concentration in US workers’ compensation and managed care, along with its purely domestic revenue base, could quickly challenge today’s valuation narrative if demand softens.

Another View On CorVel Using Our DCF Model

The picture looks different when switching from the P/E ratio to our DCF model for CorVel. At a share price of $62.56, the stock trades about 10.1% below the SWS DCF estimate of $69.56. One method suggests CorVel is a bit expensive, while the other points to a discount. Which lens do you give more weight to?

Our DCF model sets out that alternative lens in detail, including the key assumptions behind the cash flow forecasts and discount rate choices that drive this fair value range. Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out CorVel for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 52 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

If CorVel’s mixed signals on value and growth leave you unsure, that is a useful starting point rather than a problem. Act while the details are fresh in mind and compare the potential upsides against the concerns using the 2 key rewards and 1 important warning sign

Looking for more investment ideas beyond CorVel?

CorVel’s story is just one piece of your portfolio puzzle. Before moving on, take a moment to line up a few more ideas worth your attention.

• Target resilient cash generators by scanning companies with strong financial footing using the solid balance sheet and fundamentals stocks screener (48 results).
• Hunt for underappreciated opportunities by reviewing the screener containing 21 high quality undiscovered gems before other investors catch on.
• Prioritize stability and sleep-at-night potential by checking out 83 resilient stocks with low risk scores that could help balance bolder positions.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.